Abstract Library

#4187 Psychiatric and cognitive function in patients with serotonin producing neuroendocrine tumors

Introduction: Cognitive and psychiatric problems are common in cancer patients, but literature in patients with neuroendocrine tumors (NET) is scarce. Peripheral serotonin overproduction by the tumor, clinically manifesting as carcinoid syndrome, is hypothesized to be related to cognitive and psychiatric problems, through depletion of serotonin’s precursor tryptophan.

Conference:

Presenting Author: Tesselaar M

Authors: Luijendijk M, Tesselaar M, van Rossum H, Korse C, Verbeek W,

Keywords: Neuroendocrine neoplasm, carcinoid syndrome, cognitive functioning, depression, anxiety, serotonin, tryptophan, 5-HIAA,

#3475 Serum Activin A is not associated with carcinoid heart disease (CHD) in patients with neuroendocrine tumors (NET)

Introduction: CHD is a fibrotic cardiac disorder that is caused by serotonin secreted by NET, especially in the presence of liver metastases. Currently, N terminal pro B type natriuretic peptide (NT-proBNP) is used to detect cardiac damage due to CHD, yet no predictive biomarkers are available. Activin A has been identified as a potential biomarker for CHD.

Conference:

Presenting Author: Levy S

Authors: Levy S, Kilgallen A, Korse C, Oerlemans M, Sluijter J,

Keywords: CHD, carcinoid heart disease, biomarker, NT-proBNP, Activin A,

#3402 Serial liquid biopsies - the NETest - in gastroenteropancreatic NET surveillance

Introduction: Current general biomarkers are insufficient to predict the disease course in individual patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).

Conference:

Presenting Author:

Authors: van Treijen M, Korse C, Verbeek W, Tesselaar M, Valk G,

Keywords: GEP-NET, disease status, prediction, treatment response, surveillance,

#2977 Predicting Survival in Patients with a Neuroendocrine Tumor of the Small Intestine (SI-NET)

Introduction: SI-NET comprise the largest group of neuroendocrine tumors. Because of their heterogeneity, predicting survival has proven challenging. A nomogram (NG) to assess SI-NET disease specific survival (DSS) has been developed in 2010 by Modlin, et al. based on analysis of retrospective data from the Surveillance, Epidemiology and End Results (SEER) database.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Levy S, van Veenendaal L, Korse C, Verbeek W, Vriens M,

Keywords: SI-NET, Nomogram, Survival,

#1881 A Gene Expression-Based Nomogram Predicts Progression Free Survival in Small Bowel NETs

Introduction: Nomograms are predictive tools that help prognosticate. A survival nomogram has been validated for small bowel NETs. A circulating NET specific 51gene signature – the NETest – has efficacy (~95%) as a predictor of progression free survival (PFS).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Kidd M

Authors: Kidd M, Tesselaar M, Korse T, Verbeek W, Drozdov I,

Keywords: Nomogram, prognosis, NETest, PFS, grade, biomarker,